Citrine Medicine Announces Strategic Partnership to bring Alkindi� to China for Use in Pediatric Congenital ...
(World News USA)

CAMBRIDGE, Mass. and SHANGHAI, Jan. 27, 2021 /PRNewswire/ --�Citrine Medicine, a�China-based rare disease therapeutics company,�today announced that it has entered into a licensing agreement with Diurnal Group plc (AIM: DNL), a specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases. The deal provides Citrine with exclusive rights to develop, register and commercialize Alkindi� in the Greater�China market. Citrine is a therapeutics company building the first rare disease ecosystem in China by in-licensing clinically validated assets developed in the U.S. and Europe. Citrine is leveraging China`s expedited regulatory pathways to achieve rapid approval...